Formulation and Optimization of Orally Disintegrating Tablets of Sumatriptan Succinate

被引:40
|
作者
Sheshala, Ravi [1 ,2 ]
Khan, Nurzalina [1 ]
Darwis, Yusrida [1 ]
机构
[1] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town 11800, Malaysia
[2] Int Med Univ, Sch Pharm & Hlth Sci, Kuala Lumpur 57000, Malaysia
关键词
sumatriptan succinate; orally disintegrating tablet; superdisintegrant; sublimation; disintegration time; in vivo study; ORODISPERSIBLE TABLETS; PHARMACOKINETICS; MIGRAINE; AGONIST; SPRAY;
D O I
10.1248/cpb.59.920
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aims of the present research were to mask the intensely bitter taste of sumatriptan succinate and to formulate orally disintegrating tablets (ODTs) of the taste masked drug. Taste masking was performed by coating sumatriptan succinate with Eudragit EPO using spray drying technique. The resultant microspheres were evaluated for thermal analysis, yield, particle size, entrapment efficiency and in vitro taste masking. The tablets were formulated by mixing the taste masked microspheres with different types and concentrations of superdisinte-grants and compressed using direct compression method followed by sublimation technique. The prepared tablets were evaluated for weight variation, thickness, hardness, friability, drug content, water content, in vitro disintegration time and in vitro drug release. All the tablet formulations disintegrated in vitro within 37-410 s. The optimized formulation containing 5% Kollidon CL-SF released more than 90% of the drug within 15 min and the release was comparable to that of commercial product (Suminat (R)). In human volunteers, the optimized formulation was found to have a pleasant taste and mouth feel and disintegrated in the oral cavity within 41 s. The optimized formulation was found to be stable and bioequivalent with Suminat (R).
引用
收藏
页码:920 / 928
页数:9
相关论文
共 50 条
  • [41] On the BCS biowaivers of orally disintegrating tablets
    Garcia-Arieta, Alfredo
    Gordon, John
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 66 : 107 - 108
  • [42] Dissolution testing of orally disintegrating tablets
    Kraemer, Johannes
    Gajendran, Jayachandar
    Guillot, Alexis
    Schichtel, Julian
    Tuereli, Akif
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (07) : 911 - 918
  • [43] PREPARATION OF FAMOTIDINE ORALLY DISINTEGRATING TABLETS
    Olmez, Senem Sevtap
    Vural, Imran
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 38 (01) : 65 - 66
  • [44] Development and optimization of lyophilized orally disintegrating tablets using factorial design
    Ahmed, Iman Saad
    Shamma, Rehab Nabil
    Shoukri, Ragia Ali
    [J]. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2013, 18 (04) : 935 - 943
  • [45] Formulation evaluation and optimization of fast disintegrating tablets of ketorolac tromethamine
    Raina B.
    Sharma A.
    Bajwa P.S.
    [J]. Journal of Pharmaceutical Investigation, 2018, 48 (6) : 685 - 695
  • [46] Ability to function following treatment with a new fast disintegrating/rapid release formulation of sumatriptan tablets
    Cruccu, G
    Carpay, JA
    Kwong, J
    Ahmad, F
    Boswell, D
    Alderton, C
    [J]. CEPHALALGIA, 2005, 25 (08) : 664 - 664
  • [47] A new formulation for orally disintegrating tablets using a suspension spray-coating method
    Okuda, Y.
    Irisawa, Y.
    Okimoto, K.
    Osawa, T.
    Yamashita, S.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 382 (1-2) : 80 - 87
  • [48] Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation
    Laitinen, Riikka
    Suihko, Eero
    Bjorkqvist, Mikko
    Riikonen, Joakim
    Lehto, Vesa-Pekka
    Jarvinen, Kristiina
    Ketolainen, Jarkko
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2010, 36 (05) : 601 - 613
  • [49] Formulation and in vitro evaluation of pramipexole orally disintegrating tablets for pediatric restless leg syndrome
    Turkmen, Omer
    Pozharani, Leyla Beba
    Amel, Moein
    [J]. JOURNAL OF RESEARCH IN PHARMACY, 2023, 27 (05): : 1808 - 1820
  • [50] Treatment noncompliance with orally disintegrating olanzapine tablets
    Freudenreich, O
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (05): : 353 - 354